Meningitis Foundation says Pharmac must make
both the meningococcal B and ACWY vaccines available to ALL
young people
The Meningitis Foundation
Aotearoa New Zealand says this morning’s announcement from
Te Pātaka Whaioranga – Pharmac, providing widened access
to the vaccine for the deadly meningococcal B strain,
overlooks some of Aotearoa New Zealand’s most at-risk
groups.
From 1 March 2023, Pharmac proposes to fund
the meningococcal B vaccine (Bexsero) for:
§ children
up to 12 months of age (with a relevant catch-up
programme)
§ people aged 13 to 25 years who are
entering into or in their first year of
specified close-living situations (with a
limited catch-up programme).
The
Meningitis Foundation’s chair, Gerard Rushton, says that
while he welcomes access to the meningococcal B vaccine, the
devil is in the detail of Pharmac’s fine
print.
“We celebrate the decision to fund the
meningococcal B vaccine for infants, and implore Pharmac and
their sector partners to move quickly to drive uptake of the
childhood vaccine to protect our most
vulnerable.
“Looking at our rangatahi, we will
continue to see deaths related to meningococcal disease due
to the lack of a comprehensive and timely vaccination
programme.
“Pharmac will provide access to the
meningococcal B vaccine to the same narrow group of young
adults who currently have access to the meningococcal
ACW&Y vaccine. Pharmac is again overlooking significant
at-risk groups of 13-25 year-olds who are living in shared
flats, or crowded or multigenerational homes.
“This
access programme discriminates against those who chose to
enter the workforce, assume carer roles, live at home or
off-campus, or undertake vocational
training.
“Māori and Pasifika within the 13-
25-year-old age range are one of the most at-risk groups and
are again largely overlooked,” says Gerard.
The
Foundation says that protection through vaccination should
be available to all rangatahi, not just a select
few.
Funding for the proposed widened access
programmes will come into effect from 1st March 2023. The
Foundation is concerned this misses the commencement of the
academic year for secondary and tertiary institutions, a
critical time to reach our young adults, and their parents,
caregivers and whānau.
Vaccination rates set by the
Government for the ACW&Y vaccine failed to reach their
target. Earlier this year, Pharmac allowed $1.7 million
worth of meningococcal ACW&Y vaccines to go waste due to
low uptake leading to close to expiry date
vaccines.
The timing and reach of awareness campaigns
is critical to success: “A widening of access MUST be
supported by a high-profile awareness campaign by the
Ministry of Health. People need to know they, or their
family members are eligible for free vaccination,” says
Gerard.
“We urge Pharmac to make further assessments
to widen vaccine access without
delay.”
Background
In March 2022, the
Meningitis Foundation presented a petition to Dr Shane Reti,
National Spokesperson for Health, signed by 6,357 New
Zealanders. The petition urged the Government to fund both
meningococcal vaccines for the most common strains of
meningococcal disease – the B and A, C, W, & Y strains
– for all 16-year-olds before they leave school.
The
petition is a critical component of the Foundation’s
campaign calling on Parliament to make two currently
available vaccines, which cover the most common strains of
meningococcal disease, free for all young
people.
There have already been 60 cases of invasive
meningococcal disease reported in New Zealand so far this
year, including several deaths. Sixty five per cent of those
cases are Māori and Pasifika, and 80% of cases were
meningococcal B.
More information is available here.
© Scoop Media



















Discussion about this post